Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

医学 内科学 安慰剂 胃肠病学 聚乙二醇干扰素α-2a 临床终点 肝病学 乙型肝炎表面抗原 随机对照试验 慢性肝炎 免疫学 病毒 利巴韦林 乙型肝炎病毒 病理 替代医学
作者
Heiner Wedemeyer,Cihan Yurdaydın,Svenja Hardtke,Florin Alexandru Căruntu,Manuela Curescu,Kendal Yalçın,Ulus Salih Akarca,Selım Gürel,Stefan Zeuzem,Andreas Erhardt,Stefan Lüth,George Papatheodoridis,Onur Keskın,Kerstin Port,Monica Radu,Mustafa Kemal Çelen,Ramazan İdilman,Kristina Weber,Judith Stift,Ulrike Wittkop,Benjamin Heidrich,Ingmar Mederacke,Heiko von der Leyen,Hans Peter Dienes,Markus Cornberg,Armin Koch,Michael P. Manns
出处
期刊:Lancet Infectious Diseases [Elsevier]
卷期号:19 (3): 275-286 被引量:144
标识
DOI:10.1016/s1473-3099(18)30663-7
摘要

Background Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25–30% of patients only. Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppression is unknown. We aimed to explore whether prolonged treatment of HDV with 96 weeks of peginterferon would increase HDV RNA response rates and reduces post-treatment relapses. Methods We did two parallel, investigator-initiated, multicentre, double-blind randomised, controlled trials at 14 study sites in Germany, Greece, Romania, and Turkey. Patients with chronic HDV infection and compensated liver disease who were aged 18 years or older were eligible for inclusion. All patients were HBsAg positive for at least 7 months, anti-HDV positive for at least 3 months, and HDV-RNA positive at the local laboratory at the screening visit. Patients were ineligible if alanine aminotransferase levels were higher than ten times above the upper limit of normal and if platelet counts were lower than 90 000 per μL, or if they had received interferon therapy or treatment with a nucleoside and nucleotide analogue within the preceding 6 months. Patients were randomly assigned by blinded stratified block randomisation (1:1) to receive 180 μg of peginterferon alfa-2a weekly plus either TDF (300 mg once daily) or placebo for 96 weeks. The primary endpoint was the percentage of patients with undetectable HDV RNA at the end of treatment assessed by intention to treat. The trials are registered as NCT00932971 and NCT01088659. Findings Between June 24, 2009, and Feb 28, 2011, we randomly assigned 59 HDV RNA-positive patients to receive peginterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo, including 48 (40%) patients with cirrhosis to the two treatment groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the peginterferon alfa-2a plus placebo group). The primary endpoint was achieved in 28 (48%) of 59 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of 61 patients in the peginterferon alfa-2a plus placebo group (odds ratio 1·84, 95% CI 0·86–3·91, p=0·12). We recorded 944 adverse events (459 in the peginterferon alfa-2a plus TDF group and 485 in the peginterferon alfa-2a plus placebo group). The most common adverse events were haematological, behavioural (eg, fatigue), musculoskeletal, influenza-like syndromes, and psychiatric complaints. Interpretation Addition of TDF resulted in no significant improvement in HDV RNA response rates at the end of treatment. These findings highlight that alternative treatment options are needed for hepatitis D. Funding The HepNet Study-House (a project of the German Liver Foundation founded by the German Liver Foundation, the German Ministry for Education and Research, and the German Center for Infectious Disease Research), Hoffmann-La Roche, and Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cy完成签到 ,获得积分10
1秒前
Lucas应助飞快的金鑫采纳,获得10
1秒前
1秒前
zai发布了新的文献求助10
2秒前
JiaHui发布了新的文献求助20
2秒前
传奇3应助gao456789采纳,获得10
2秒前
于世不凡发布了新的文献求助10
3秒前
小熊完成签到,获得积分10
3秒前
zhangxinyu完成签到,获得积分10
4秒前
4秒前
斯文媚颜发布了新的文献求助10
5秒前
cookienin发布了新的文献求助30
6秒前
Seven37完成签到,获得积分10
6秒前
aleph完成签到,获得积分10
6秒前
LLLLLLL完成签到,获得积分10
9秒前
情怀应助嘟嘟嘟采纳,获得30
10秒前
mingruiqi发布了新的文献求助10
10秒前
CipherSage应助古果采纳,获得10
10秒前
10秒前
于忠波发布了新的文献求助10
10秒前
11秒前
小靳发布了新的文献求助10
11秒前
活力的映易完成签到,获得积分10
11秒前
洁净钢笔发布了新的文献求助10
12秒前
慎独完成签到,获得积分20
12秒前
顺利雪糕完成签到,获得积分10
12秒前
yuancaix完成签到,获得积分10
12秒前
彩虹关注了科研通微信公众号
13秒前
13秒前
mlzmlz完成签到,获得积分10
14秒前
14秒前
ABC2023发布了新的文献求助10
14秒前
14秒前
共享精神应助花骨朵采纳,获得10
15秒前
16秒前
还单身的谭完成签到,获得积分10
16秒前
大胆的寻菡完成签到,获得积分10
16秒前
科目三应助合适的梦之采纳,获得30
16秒前
16秒前
无花果应助吴雨涛采纳,获得10
17秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3152657
求助须知:如何正确求助?哪些是违规求助? 2803891
关于积分的说明 7856198
捐赠科研通 2461571
什么是DOI,文献DOI怎么找? 1310444
科研通“疑难数据库(出版商)”最低求助积分说明 629205
版权声明 601782